Hardy Alexander's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 16,570 Common Stock done at an average price of $55.0 . Disclosure was reported to the exchange on Dec. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.03 per share. | 01 Dec 2025 | 16,570 | 159,388 (0%) | 0% | 55.0 | 911,847 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 54.14 per share. | 01 Dec 2025 | 375 | 175,958 (0%) | 0% | 54.1 | 20,301 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 61,750 | 61,750 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 44,360 | 175,583 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.44 per share. | 14 Mar 2025 | 2,933 | 131,223 (0%) | 0% | 69.4 | 203,668 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Hardy Alexander | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.03 per share. | 29 Nov 2024 | 14,295 | 134,156 (0%) | 0% | 66.0 | 943,899 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 56.01 per share. | 29 Nov 2024 | 300 | 148,451 (0%) | 0% | 56.0 | 16,802 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 44,050 | 44,050 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 32,780 | 148,151 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 150,529 | 150,529 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 68,039 | 68,039 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 47,332 | 115,371 (0%) | 0% | 0 | Common Stock |